A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation

Last updated: January 4, 2021
Sponsor: M.D. Anderson Cancer Center
Overall Status: Active - Not Recruiting

Phase

3

Condition

Urologic Cancer

Prostate Cancer

Prostate Cancer, Early, Recurrent

Treatment

N/A

Clinical Study ID

NCT00667888
ID00-381
NCI-2010-01456
  • Male

Study Summary

The goal of this clinical research study is to compare using external beam radiotherapy with intensity modulated beams for fewer days at a higher dose per day to the same type of therapy for more days at a lower dose per day in the treatment of prostate cancer. The safety of these treatments will also be studied and compared.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Biopsy proof of adenocarcinoma of the prostate.
  2. Bone scan (If PSA >10 ng/ml or T3 disease) within 3 months of starting androgenablation or signing protocol consent if no androgen ablation.
  3. CT-scan of pelvis (If Stage T3 disease) within 3 months of starting androgen ablationor signing protocol consent if no androgen ablation.
  4. Suitable medical condition; Zubrod <2.
  5. Pretreatment PSA </=20 ng/ml. If PSA <4, must have Gleason greater than or equal to 7and/or Stage T2b-T2c. PSA within 30 days of signing protocol consent. If neoadjuvantandrogen ablation has been given, then the preandrogen ablation PSA should be used forstratification.
  6. Clinical (palpable) Stage T1b - T3b disease (1992 AJCC staging system).
  7. While a transrectal ultrasound will be obtained before treatment, the staging will notbe based on these findings. If palpable T3 disease is present, then must have Gleasonscore <8 and pretreatment PSA less than or equal to 10 ng/ml
  8. Gleason score <10.
  9. If Gleason score 8 or 9, then must have stage T1/T2 disease and pretreatment PSA lessthan or equal to 10 ng/ml.
  10. The patient must be able to understand the protocol and adhere to follow-up at 6-monthintervals for the first 2 years and at yearly intervals thereafter.
  11. Informed consent must be given.
  12. Patients randomized to Arm 1 may also participate in protocol 2004-0428.

Exclusion

Exclusion Criteria:

  1. Prior pelvic radiotherapy.
  2. Greater than 4 months of prior hormone ablation therapy.
  3. Prior or planned radical prostate surgery.
  4. Clinical, radiographic or pathologic evidence of nodal or distant metastatic disease.
  5. Concurrent, active malignancy, other than nonmetastatic skin cancer or early stage -chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma).If a prior malignancy is in remission for greater than or equal to 5 yr then thepatient is eligible.
  6. Zubrod status greater than or equal to 2.
  7. Pretreatment PSA >20 ng/ml.
  8. Gleason score of 10.
  9. Palpable stage T3c (seminal vesicle involvement) or T4 disease.

Study Design

Total Participants: 225
Study Start date:
January 03, 2001
Estimated Completion Date:
October 31, 2021

Study Description

Patients in this study will be randomly picked (as in the toss of a coin) to be in one of two treatment groups. There is an equal chance of being in either group.

Patients in Group 1 will be treated with intensity modulated radiotherapy (IMRT). These patients will receive 42 treatments, 5 days per week, over 8.5 weeks. This method has become the standard treatment at M.D. Anderson Cancer Center.

Patients in Group 2 will also be treated with IMRT. However, these patients will only receive 30 treatments, 5 days per week, over 6 weeks. The dose per day for Group 2 patients is higher than for Group 1 and has the possibility of killing more tumor cells.

Each external beam treatment requires about 10-20 minutes. However, patients can expect to spend 20 - 30 minutes on the treatment table because imaging measurements of prostate position will be done before each treatment. The total time in the radiation department each treatment day will be about an hour.

After the radiotherapy is completed, patients will have a PSA blood test every 3 months for 2 years, then every 6 months for Years 3 - 5, then annually. They will be examined every 6 months during the first 2 years beginning 3 months after the completion of treatment, then annually. A needle biopsy of the prostate will be performed if these tests suggest recurrence.

This is an investigational study. 225 patients will take part in this study. This study will take place at M. D. Anderson and possibly some affiliated hospitals.

Connect with a study center

  • University of Texas MD Anderson Cancer Center

    Houston, Texas 77030
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.